Tradestie Institutional Equity Comparison Engine
ATPC vs CDT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ATPC Overall Edge
ATPC Captures Institutional Edge (2โ1 Pillars ยท 4โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Agape ATP Corporation Common Stock (ATPC) driven by superior Momentum & Technical, Options & Structure while CDT counters with relative strength in Growth & Margin. Fundamentally, ATPC trades at N/M Forward P/E with -239.0% operating margin (-93.4% YoY revenue) versus CDT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ATPC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CDT sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ATPC N/M vs CDT N/M Fwd P/E
Growth & Margin Winner
CDT
Op Margin -239.0% vs 0.0% ยท YoY -93.4% vs +0.0%
Momentum & Technical Winner
ATPC
1Y -8.7% vs -86.8% ยท 52W Pos 13% vs 2%
Options & Structure Winner
ATPC
UNCLASSIFIED (N/A IV) vs BREAKDOWN (N/A IV)
ATPC
NASDAQ
Agape ATP Corporation Common Stock
Services-Health Services
$1.16
-15.94% 1D
Market Cap
$1.4M
1M Return
-18.31%
1Y Return
-8.66%
Forward P/E
N/M
Unified AI Score
51.6 / 100
HOLD
Tech 71.0
Fund 47.0
Flow 50.0
Mom 54.0
CDT
NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap
$507,528
1M Return
+76.79%
1Y Return
-86.78%
Forward P/E
N/M
Unified AI Score
31.6 / 100
SELL
Tech 15.0
Fund 37.0
Flow 50.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ATPC -8.66%
CDT -86.78%
Spread: +76.01 pp (ATPC Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ATPC TTM Op. Margin: -239.0%
CDT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ATPC vs CDT. Trailing 12-month operating profitability (ATPC -239.0% vs CDT 0.0%) and valuation multiples (ATPC N/M vs CDT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ATPC | CDT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.4M | $507,528 | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -93.4% | +0.0% | Higher Growth | CDT |
| Operating Margin (TTM) Profitability | -239.0% | 0.0% | Higher Margin | CDT |
| Net Profit Margin Profitability | -86.3% | 0.0% | Higher Margin | CDT |
| Return on Equity (ROE) Capital Efficiency | -5.5% | -69.7% | Higher ROE | ATPC |
| 52-Week Range Position Momentum | 13% ($0โ$8) | 2% ($0โ$11) | Stronger Trend | ATPC |
| Beta / 30D Volatility Risk Regime | 0.83ฮฒ ยท 135% Vol | -17.75ฮฒ ยท 10175% Vol | Lower Realized Risk | ATPC |
| Unified Institutional Score Composite Signal | 51.6 / 100 (HOLD) | 31.6 / 100 (SELL) | Higher Composite | ATPC |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ATPC vs CDT Buy Guide
ATPC
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CDT
BREAKDOWN
163d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ATPC nor CDT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.